Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from TransMedics Group ( (TMDX) ) is now available.
On May 20, 2026, TransMedics Group, Inc. shareholders re-elected eight directors, including founder and CEO Waleed Hassanein, M.D., along with board members such as James R. Tobin and Merilee Raines, to serve until the 2027 annual meeting. Investors also expressed continued confidence in leadership by approving, on an advisory basis, the compensation packages for the company’s named executive officers.
Shareholders backed an amendment to the company’s 2019 Stock Incentive Plan, signaling support for the continued use of equity-based awards as a tool for attracting and retaining talent in a competitive medtech market. They further ratified the appointment of PricewaterhouseCoopers LLP as TransMedics’ independent auditor for the fiscal year ending December 31, 2026, reinforcing continuity in the company’s financial oversight and governance framework.
The most recent analyst rating on (TMDX) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on TransMedics Group stock, see the TMDX Stock Forecast page.
Spark’s Take on TMDX Stock
According to Spark, TipRanks’ AI Analyst, TMDX is a Neutral.
The score is primarily supported by strong underlying profitability/cash generation and reiterated 2026 growth guidance, but is held back by a very weak technical trend, an expensive valuation, and near-term margin pressure/execution risks highlighted on the earnings call.
To see Spark’s full report on TMDX stock, click here.
More about TransMedics Group
TransMedics Group, Inc. operates in the medical technology sector, focusing on systems that support organ transplantation and related clinical workflows. The company’s products and services are aimed at improving the preservation, transportation, and utilization of donor organs, positioning it within a specialized niche of the healthcare and life sciences market that serves transplant centers and hospital networks.
Average Trading Volume: 1,284,568
Technical Sentiment Signal: Sell
Current Market Cap: $2.35B
See more data about TMDX stock on TipRanks’ Stock Analysis page.